Naim Abu-Freha

Dr. Naim Abu-Freha

Soroka University Medical Center
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
GTGadeer Ali Taha
Gadeer Ali Taha
ELEzra Levy
Ezra Levy
NANaim Abu-Freha
Naim Abu-Freha
Hepatitis C Virus (HCV) infection is a leading etiology of liver cirrhosis and its associated complications, namely, decompensated cirrhosis. As such, hepatitis C potentially necessitates liver transplantation and may result in death. Recently, HCV treatment has evolved. Current HCV treatment is effective in curing HCV; some of the agents are pan-genotypic. Numerous countries have adopted an initiative to eliminate HCV. Achieving elimination poses many challenges; it requires improved availability and accessibility of pan-genotypic therapy. Barriers exist at the level of the collective healthcare system and at the level of the individual healthcare providers and patients. Therefore, organized national and local efforts are needed. Surmounting these barriers calls for interventions concerning screening, linkage to care, and treatment delivery. Pertinent barriers include inadequate availability of screening, ill-equipped laboratory testing before treatment, and insufficient access to treatment. Interventions should seek to decentralize laboratory testing and treatment provision, increase funding for resources and personnel, and spread awareness. Special consideration should be allocated to at-risk populations, such as intravenous drug users, refugees, and prisoners. Computerized medical filing and telemedicine have the potential to refine HCV management by enhancing detection, availability, accessibility, and cost-effectiveness.

2 August 2019 in Journal of Community Genetics
Verified
Journal Article
Closed access
SSSarah Singer
Sarah Singer
NDNadav Davidovitch
Nadav Davidovitch
YFYasmeen Abu Fraiha
Yasmeen Abu Fraiha
NANaim Abu-Freha
Naim Abu-Freha

20 April 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
VSVered Slonim-Nevo
Vered Slonim-Nevo
OSOrly Sarid
Orly Sarid
MFMichael Friger
Michael Friger
DSDoron Schwartz
Doron Schwartz
RSRuslan Sergienko
Ruslan Sergienko
AFAlexander Fich
Alexander Fich
Psychological distress increases morbidity in ulcerative colitis (UC) and Crohn’s disease (CD). We examined whether social support is associated with distress and disease activity. There were 110 UC and 147 CD patients who completed sociodemography, economic status, disease activity (UC: Patient Simple Clinical Colitis Activity Index (P-SCCAI), CD: Patient Harvey-Bradshaw Index . (P-HBI), Multidimensional Scale of Perceived Social Support (MSPSS), Brief Symptom Inventory with Global Severity Index (GSI) of psychological distress, and 2 health-related quality-of-life scales (SF-36 Physical Health and Mental Health, and Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Analysis included multiple linear regressions and structural equation modeling. Disease activity was mild: UC: P-SCCAI 2.9 ± 3.5, CD: P-HBI 4.7 ± 4.7. Physical Health was better in UC 46.6 ± 11.4 versus CD 43.7 ± 10.9 (P < .02). GSI was lower in UC 0.6 ± 0.7 than CD 0.8 ± 0.7 (P = .002). MSPSS total score was equal in UC (5.9 ± 1.2) and CD (5.9 ± 1.1). MSPSS total correlated with P-SCCAI (correlation coefficient ‒0.240), GSI in UC (‒0.470), and GSI in CD (‒0.333). Economic status correlated with GSI in UC (‒0.408) and CD (‒0.356). MSPSS predicted GSI, Mental Health, and SIBDQ in UC and CD, and predicted P-SCCAI but not P-HBI; economic status predicted all the foregoing. Path analysis depicted GSI as mediating the effects of MSPSS and economic status on disease activity in both UC and CD. MSPSS (UC: β ‒0.34, CD: β ‒0.37) and economic status (UC: β ‒0.38, CD: β ‒0.22) reduced GSI, which then increased the disease activity (UC: β 0.56, CD: β 0.42). Social support and economic status are linked to UC and CD patients’ well-being. Interventions addressing these issues should be part of management.

28 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OSOrly Sarid
Orly Sarid
VSV Slonim-Nevo
V Slonim-Nevo
APA Pereg
A Pereg
MFM Friger
M Friger
RSR Sergienko
R Sergienko
I(Israeli IBD Research Nucleus (IIRN)
Israeli IBD Research Nucleus (IIRN)
To identify coping strategies and socio-demographics impacting satisfaction with life and quality of life in Crohn’s disease (CD). 402 patients completed the Patient Harvey-Bradshaw Index, Brief COPE Inventory, Satisfaction with Life Scale (SWLS), Short Inflammatory Bowel Disease Questionnaire (SIBDQ). We performed structural equation modeling (SEM) of mediators of quality of life and satisfaction with life. The cohort comprised: men 39.3%, women 60.1%; P-HBI 4.75 and 5.74 (p = 0.01). In inactive CD (P-HBI≤4), both genders had SWLS score 23.8; men had SIBDQ score 57.4, women 52.6 (p = 0.001); women reported more use of emotion-focused, problem-focused and dysfunctional coping than men. In active CD, SWLS and SIBDQ scores were reduced, without gender differences; men and women used coping strategies equally. A SEM model (all patients) had a very good fit (X2(6) = 6.68, p = 0.351, X2/df = 1.114, SRMR = 0.045, RMSEA = 0.023, CFI = 0.965). In direct paths, economic status impacted SWLS (β = 0.39) and SIBDQ (β = 0.12), number of children impacted SWLS (β = 0.10), emotion-focused coping impacted SWLS (β = 0.11), dysfunctional coping impacted SWLS (β = –0.25). In an indirect path, economic status impacted dysfunctional coping (β = –0.26), dysfunctional coping impacted SIBDQ (β = –0.36). A model split by gender and disease activity showed that in active CD economic status impacted SIBDQ in men (β = 0.43) more than women (β = 0.26); emotional coping impacted SWLS in women (β = 0.36) more than men (β = 0.14). Gender differences in coping and the impacts of economic status and emotion-focused coping vary with activity of CD. Psychological treatment in the clinic setting might improve satisfaction with life and quality of life in CD patients.

17 May 2022 in European Journal of General Practice
Verified
Journal Article
Open access
NANaim Abu-Freha
Naim Abu-Freha
BJBinil Mathew Jacob
Binil Mathew Jacob
AEAli Elhoashla
Ali Elhoashla
ZAZaid Afawi
Zaid Afawi
TATalab Abu-Hammad
Talab Abu-Hammad
OEOhad Etzion
Ohad Etzion
Hepatitis C Virus (HCV) is a common cause of chronic liver disease and its ensuing complications. In the last years, there has been a revolution of the treatment for patients with HCV regarding eff...

27 February 2018 in Cancers
Verified
Journal Article
Open access
PDF file
SLSergio Lamprecht
Sergio Lamprecht
ISIna SigalBatikoff
Ina SigalBatikoff
SSShraga Shany
Shraga Shany
NANaim Abu-Freha
Naim Abu-Freha
ELEduard Ling
Eduard Ling
AFAlexander Fich
Alexander Fich
It is well recognized that cancer cells subvert the phenotype of stromal naïve fibroblasts and instruct the neighboring cells to sustain their growth agenda. The mechanisms underpinning the switch of fibroblasts to cancer-associated fibroblasts (CAFs) are the focus of intense investigation. One of the most significant hallmarks of the biological identity of CAFs is that their tumor-promoting phenotype is stably maintained during in vitro and ex vivo propagation without the continual interaction with the adjacent cancer cells. In this review, we discuss robust evidence showing that the master cytokine Transforming Growth Factor-β1 (TGFβ-1) is a prime mover in reshaping, via epigenetic switches, the phenotype of stromal fibroblasts to a durable state. We also examine, in detail, the pervasive involvement of TGFβ-1 signaling from both cancer cells and CAFs in fostering cancer development, taking colorectal cancer (CRC) as a paradigm of human neoplasia. Finally, we review the stroma-centric anticancer therapeutic approach focused on CAFs—the most abundant cell population of the tumor microenvironment (TME)—as target cells.